Medical Device - Revolutionary Wound Care Product $30 million for negotiated equity - $10 Million of investment insured by OPIC (Overseas Private Investment Corporation) which helps U.S. businesses invest overseas, fosters economic development in new and emerging markets, complements the private sector in managing the risks associated with foreign direct investment, and supports U.S. foreign policy. The Company specializes in the research, design, manufacture, and marketing of wound care treatment and prevention products for advanced-stage wounds which has proven to have phenomenal success. Adjunctive therapy for the following conditions: 1. Skin ulcerations due to diabetes, venous statis, post surgical infections and gangrenous lesions 2. Biological warfare related lesions, (for example, smallpox and dermal anthrax) 3. Pressure ulcers 4. Amputations and infected stumps 5. Skin grafts 6. Burns (electrical, chemical and thermal) 7. Frostbite The Company has developed a suite of five products. Three of them are designed to assist in the healing or prevention of skin ulcers. Skin ulcers are a common and serious ailment associated with the large and growing population of wheelchair bound, bed-ridden and diabetic patients as well as some new diseases such as necrotizing fasciitis. Company already has 2 FDA-approved products (Class II and Class III), several patents, and $9 million invested in R&D and clinical validation. The Company, known for its highly advanced R&D efforts, developed these products in collaboration with Sandia National Laboratories (Sandia) as part of the U.S. Department of Energy (DOE) Cooperative Research and Development Agreement (CRADA) program. To date, the Company has been awarded a total of $14.5 million in CRADA grant funding and future commitments that do not need to be paid back. This access to one of the world’s premier engineering facilities (Sandia) has resulted in the cost-effective development of quality engineered products through the commercial adaptation of highly advanced defense related technology that has revolutionized wound care management and treatment, and also have the potential for bio-terrorism, homeland defense, and U.S. military battlefield applications. Product is currently being used by the U.S. military in hospitals and in the field in Iraq and around the world. Product has been accepted by the Department of Homeland Security as a cost-effective first responder medical device in its strategic protection arsenal. Company has a worldwide U.S. government contract and other national/regional health care organization contracts to stimulate company sales. There is very strong interest in both U.S. military, Dept. of Labor and the Dept. of Homeland Defense officials. The U.S. government has signed a Worldwide Federal Supply Schedule Contract for one product because of its effectiveness in healing wounds at a lower cost than other treatment methods. There were over 25 clinical studies in the past 15 years supporting its effectiveness, and its usefulness in treating wounds resulting from bioterrorism, chemical, and nuclear incidents. Besides for use by military in field operations and medical facilities home and abroad, the product will also be used as a portable isolation chamber in domestic emergencies responded by ambulances, fire/rescue and various emergency response teams and hospitals. One product is in limited commercial production and poised for national rollout within 90 days of capital raise. The wound care market is over 7,000,000 U.S. patients suffering from chronic wounds, (4 million from pressure ulcers, 1 million from diabetes foot/leg ulcers, 0.6 million from burns, 1.4 million from other surgical wounds, skin grafts, etc.) The Domestic chronic wound care is a $16-$24 billion industry. Wound care patients are expected to increase dramatically as population ages and approximately 50 million worldwide suffer from various wound-related illnesses. Company has a contract with a multibillion dollar distribution company for military sales.